|
Post by sla55 on Feb 6, 2018 8:04:48 GMT -5
WESTLAKE VILLAGE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity, effective February 12. Dr. Kendall will report directly to Michael Castagna, Pharm.D., Chief Executive Officer, and will join the company's executive leadership team. He will be based out of MannKind's Westlake Village, California headquarters.
"David is a world renowned diabetes expert and represents an important addition to our executive leadership team," said Castagna, Chief Executive Officer of MannKind. "His extensive experience in diabetes research, development, and clinical care in both U.S. and international markets, will be instrumental in helping us achieve the growth potential that we believe Afrezza® clearly possesses."
Dr. Kendall's career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and during that time was responsible for all medical affairs activities and guided research and development strategy across multiple geographies. In this role, he worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors. Prior to joining Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. He received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College.
"The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes," said Dr. Kendall. "Afrezza is the only inhaled fast-acting mealtime insulin on the market, and offers the right patients a flexible, safe, and effective treatment option. I'm thrilled to join MannKind, and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes."
|
|
|
Post by kbrion77 on Feb 6, 2018 8:19:32 GMT -5
WESTLAKE VILLAGE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity, effective February 12. Dr. Kendall will report directly to Michael Castagna, Pharm.D., Chief Executive Officer, and will join the company's executive leadership team. He will be based out of MannKind's Westlake Village, California headquarters. "David is a world renowned diabetes expert and represents an important addition to our executive leadership team," said Castagna, Chief Executive Officer of MannKind. "His extensive experience in diabetes research, development, and clinical care in both U.S. and international markets, will be instrumental in helping us achieve the growth potential that we believe Afrezza® clearly possesses." Dr. Kendall's career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and during that time was responsible for all medical affairs activities and guided research and development strategy across multiple geographies. In this role, he worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors. Prior to joining Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. He received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College. "The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes," said Dr. Kendall. "Afrezza is the only inhaled fast-acting mealtime insulin on the market, and offers the right patients a flexible, safe, and effective treatment option. I'm thrilled to join MannKind, and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes." Great hire for Afrezza, but what about advancing the pipeline? We all get if Afrezza doesn't succeed the ship goes down but this is more of a Chief Diabetes Officer.
|
|
|
Post by LosingMyBullishness on Feb 6, 2018 8:50:50 GMT -5
IMO they bought his network. Mike is aiming to balance all his elements in the pipeline. He needed an important/expensive role to push Afrezza. There are barriers right now and I assume that he tries to get past them by improving acceptance and awareness. That is more needed than an operational guy running the pipeline in the role of a CMO.
|
|
|
Post by kball on Feb 6, 2018 8:57:02 GMT -5
"The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes," said Dr. Kendall. "Afrezza is the only inhaled fast-acting mealtime insulin on the market, and offers the right patients a flexible, safe, and effective treatment option. I'm thrilled to join MannKind, and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes." Is this statement intended to expand its reach or somewhat narrow it? Or is it mostly sort of a sideways acknowledgment of the breathing issues, smoking warning? I found it a little oddly worded
|
|
|
Post by kite on Feb 6, 2018 8:58:39 GMT -5
"The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes," said Dr. Kendall. "Afrezza is the only inhaled fast-acting mealtime insulin on the market, and offers the right patients a flexible, safe, and effective treatment option. I'm thrilled to join MannKind, and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes." Is this statement intended to expand its reach or somewhat narrow it? Or is it mostly sort of a sideways acknowledgment of the breathing issues, smoking warning? I found it a little oddly worded Might be analyzing it too much...
|
|
|
Post by cjm18 on Feb 6, 2018 8:58:40 GMT -5
This hire is an absolute homerun. His connections and expertise will help afrezza. And that’s what we need right now. It also speaks to the company and afrezza that mike could recruit someone of his credibility and status.
|
|
|
Post by kball on Feb 6, 2018 9:06:23 GMT -5
Is this statement intended to expand its reach or somewhat narrow it? Or is it mostly sort of a sideways acknowledgment of the breathing issues, smoking warning? I found it a little oddly worded Might be analyzing it too much... Possibly. But written words i always assume carry greater substance than those spoken. As these kinds of things are edited to say exactly what is intended, whereas verbally (in interviews and such) thoughts and ideas usually (almost always) aren't as well thought out. HUMOROUS NOTE: I've edited this post 3 times now and it still isn't how i'd like it (used the word 'thought' twice in last part of it)
|
|
|
Post by uvula on Feb 6, 2018 9:10:23 GMT -5
So maybe Lilly will acquire mnkd?
|
|
|
Post by uvula on Feb 6, 2018 9:12:05 GMT -5
Apparently if I type in multiple question marks my phone turns them into frowning emojis. This was not intentional.
|
|
|
Post by mango on Feb 6, 2018 9:21:22 GMT -5
Awesome addition to the team. I'm very impressed.
I also thought the wording "the right patients" was odd.
Wonder what he thinks about the first-phase insulin response.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 6, 2018 9:31:03 GMT -5
Very good hire. On the 29th, the company posted for several mid-level finance professionals and this group would add $1mm annually to the payroll in cash comp alone. We know more money will be coming in, when, how and how much remains to be seen. Still though, in order for Mannkind to succeed, Afrezza sales need to pick up. If we raise another $70mm or so, given the burn rate, that will get us to late '18 and unless Afrezza sales start to grow at a much quicker rate, another financing toward the end of the year so if this is the playbook, the dilution continues.
|
|
|
Post by porkini on Feb 6, 2018 11:07:44 GMT -5
Awesome addition to the team. I'm very impressed. I also thought the wording "the right patients" was odd. Wonder what he thinks about the first-phase insulin response. I don't find it odd considering that it is the official press release/announcement from MNKD and as such, they probably need to be careful about how things are worded.
|
|
|
Post by od on Feb 6, 2018 11:22:21 GMT -5
Awesome addition to the team. I'm very impressed. I also thought the wording "the right patients" was odd. Wonder what he thinks about the first-phase insulin response. I don't find it odd considering that it is the official press release/announcement from MNKD and as such, they probably need to be careful about how things are worded. MD or not, as a MNKD employee, comments about a product must consider labeling.
|
|
|
Post by hans on Feb 6, 2018 11:43:50 GMT -5
I just can't help to think that bringing on David Kendall as CMO with all his lifelong diabetes experience possibly points to MNKD selling off technosphere and concentrating fully on Afrezza.
|
|
|
Post by thekid2499 on Feb 6, 2018 11:46:28 GMT -5
Awesome addition to the team. I'm very impressed. I also thought the wording "the right patients" was odd. Wonder what he thinks about the first-phase insulin response. Agree, they should have just said: and offers patients a flexible, safe, and effective treatment option.
|
|